Eli Lilly Faces Stock Decline After Q3 Revenue Miss and Weak Zepbound Sales

Reported 27 days ago

Eli Lilly and Company (LLY) saw its stock fall in premarket trading after reporting third quarter results that fell short of revenue expectations, largely due to disappointing sales of its weight loss drug, Zepbound. The company also reduced its profit forecast for the year.

Source: YAHOO

View details

You may also interested in these wikis

Back to all Wikis